images/About_IAVI/kavi-researchers-testtubes-overhead.jpgResearchers examine samples at the Kenya AIDS Vaccine Initiative, an IAVI partner clinical research center in Nairobi, Kenya. Photo credit: Sokomoto Photography

The International AIDS Vaccine Initiative (IAVI) is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV and tuberculosis. Our mission is to translate scientific discoveries into affordable, accessible public health solutions for the people who need them most.

Through scientific and clinical research in Africa, India, Europe, and the U.S., IAVI is pioneering an access-first approach to biomedical innovation, developing vaccines and antibodies in and for the developing world and seeking to accelerate their introduction in low-income countries.

IAVI’s programs and partnerships are grounded in the regions of the world where the disease burden is the greatest, and our approach emphasizes sustainability. Our network of clinical research center partners in Africa and India helps strengthen in-country research capacity and supports the training and education of the next generation of scientists. The global impact of our science includes fundamental contributions to understanding the biology of HIV infection, which IAVI and others are applying toward advancing vaccine science and immunology.

IAVI accelerates scientific discovery and development by fostering unique collaborations among academia, industry, local communities, governments, and funders to explore new and better ways to address public health threats that disproportionately affect people living in poverty.

IAVI’s global reach, including its clinical research network in five countries in sub-Saharan Africa and in India, has allowed IAVI to make fundamental contributions to understanding the epidemiology, transmission, virology, and immunology of HIV. This work played a key role in facilitating the design of promising HIV vaccine candidates, as well as the discovery of broadly neutralizing antibodies that are now being advanced as promising approaches for HIV prevention. IAVI’s integrated capabilities in vaccine and antibody discovery, development, and clinical research take advantage of biopharmaceutical industry expertise to accelerate the development and testing of prevention methods for HIV and other diseases. Through the Product Development Center, IAVI supports external researchers with technical and scientific expertise to accelerate the development of their own products.

Learn more about IAVI’s founding and history.

Financial and Operational Highlights

  • Approximately 200 employees (~80 located at Headquarters in New York City).
  • Offices in Amsterdam, Cape Town, Delhi, Johannesburg, Nairobi, and New York City, along with laboratories in Brooklyn, Delhi, La Jolla, and London.
  • Total revenue of $100.6 million.